VA HB570 | 2024 | Regular Session
Status
Spectrum: Partisan Bill (Democrat 27-0)
Status: Vetoed on April 8 2024 - 100% progression
Action: 2024-04-17 - House sustained Governor's veto
Text: Latest bill text (Enrolled) [HTML]
Status: Vetoed on April 8 2024 - 100% progression
Action: 2024-04-17 - House sustained Governor's veto
Text: Latest bill text (Enrolled) [HTML]
Summary
Prescription Drug Affordability Board established; drug cost affordability review. Establishes the Prescription Drug Affordability Board for the purpose of protecting the citizens of the Commonwealth and other stakeholders within the health care system from the high costs of prescription drug products. The bill requires the Board to meet in open session at least four times annually, with certain exceptions and requirements enumerated in the bill. Members of the Board are required to disclose any conflicts of interest, as described in the bill. The bill also creates a stakeholder council for the purpose of assisting the Board in making decisions related to drug cost affordability. The bill tasks the Board with identifying prescription, generic, and other drugs, as defined in the bill, that are offered for sale in the Commonwealth and, at the Board's discretion, conducting an affordability review of any prescription drug product. The bill lists factors for the Board to consider that indicate an affordability challenge for the health care system in the Commonwealth or high out-of-pocket costs for patients. The bill also provides that any person aggrieved by a decision of the Board may request an appeal of the Board's decision and that the Attorney General has authority to enforce the provisions of the bill. The bill provides that the Board shall establish no more than 12 upper payment limit amounts annually between January 1, 2025, and January 1, 2028. Prescription Drug Affordability Board established; drug cost affordability review. Establishes the Prescription Drug Affordability Board for the purpose of protecting the citizens of the Commonwealth and other stakeholders within the health care system from the high costs of prescription drug products. The bill requires the Board to meet in open session at least four times annually, with certain exceptions and requirements enumerated in the bill. Members of the Board are required to disclose any conflicts of interest, as described in the bill. The bill also creates a stakeholder council for the purpose of assisting the Board in making decisions related to drug cost affordability. The bill tasks the Board with identifying prescription, generic, and other drugs, as defined in the bill, that are offered for sale in the Commonwealth and, at the Board's discretion, conducting an affordability review of any prescription drug product. The bill lists factors for the Board to consider that indicate an affordability challenge for the health care system in the Commonwealth or high out-of-pocket costs for patients. The bill also provides that any person aggrieved by a decision of the Board may request an appeal of the Board's decision and that the Attorney General has authority to enforce the provisions of the bill. The bill provides that the Board shall establish no more than 12 upper payment limit amounts annually between January 1, 2025, and January 1, 2028. The bill requires the Board to report its findings and recommendations to the General Assembly twice annually, beginning on July 1, 2025, and December 31, 2025. Provisions of the bill shall apply to state-sponsored and state-regulated health plans and health programs and obligate such policies to limit drug payment amounts and reimbursements to an upper payment limit amount set by the Board, if applicable, following an affordability review. The bill specifies that Medicare Part D plans shall not be bound by such decisions of the Board. The bill also requires the nonprofit organization contracted by the Department of Health to provide prescription drug price transparency to provide the Board access to certain data reported by manufacturers. The bill has a delayed effective date of January 1, 2025, and is identical to
Title
Prescription Drug Affordability Board; established, drug cost affordability review, report.
Sponsors
Roll Calls
2024-03-05 - Senate - Senate: Passed Senate (25-Y 15-N) (Y: 25 N: 15 NV: 0 Abs: 0) [PASS]
2024-03-04 - Senate - Senate: Constitutional reading dispensed (40-Y 0-N) (Y: 40 N: 0 NV: 0 Abs: 0) [PASS]
2024-02-29 - Senate - Senate: Reported from Finance and Appropriations (10-Y 4-N) (Y: 10 N: 4 NV: 0 Abs: 0) [PASS]
2024-02-26 - Senate - Senate: Reported from Commerce and Labor (10-Y 5-N) (Y: 10 N: 5 NV: 0 Abs: 0) [PASS]
2024-02-22 - Senate - Senate: Rereferred from Education and Health (12-Y 0-N) (Y: 12 N: 0 NV: 0 Abs: 0) [PASS]
2024-02-13 - House - House: VOTE: Passage (52-Y 46-N) (Y: 52 N: 46 NV: 0 Abs: 2) [PASS]
2024-02-09 - House - House: Reported from Appropriations (11-Y 9-N) (Y: 11 N: 9 NV: 0 Abs: 2) [PASS]
2024-02-07 - House - House: Subcommittee recommends reporting (5-Y 2-N) (Y: 5 N: 2 NV: 0 Abs: 2) [PASS]
2024-02-01 - House - House: Reported from Labor and Commerce with substitute (12-Y 10-N) (Y: 12 N: 10 NV: 0 Abs: 0) [PASS]
2024-03-04 - Senate - Senate: Constitutional reading dispensed (40-Y 0-N) (Y: 40 N: 0 NV: 0 Abs: 0) [PASS]
2024-02-29 - Senate - Senate: Reported from Finance and Appropriations (10-Y 4-N) (Y: 10 N: 4 NV: 0 Abs: 0) [PASS]
2024-02-26 - Senate - Senate: Reported from Commerce and Labor (10-Y 5-N) (Y: 10 N: 5 NV: 0 Abs: 0) [PASS]
2024-02-22 - Senate - Senate: Rereferred from Education and Health (12-Y 0-N) (Y: 12 N: 0 NV: 0 Abs: 0) [PASS]
2024-02-13 - House - House: VOTE: Passage (52-Y 46-N) (Y: 52 N: 46 NV: 0 Abs: 2) [PASS]
2024-02-09 - House - House: Reported from Appropriations (11-Y 9-N) (Y: 11 N: 9 NV: 0 Abs: 2) [PASS]
2024-02-07 - House - House: Subcommittee recommends reporting (5-Y 2-N) (Y: 5 N: 2 NV: 0 Abs: 2) [PASS]
2024-02-01 - House - House: Reported from Labor and Commerce with substitute (12-Y 10-N) (Y: 12 N: 10 NV: 0 Abs: 0) [PASS]
History
| Date | Chamber | Action |
|---|---|---|
| 2024-04-17 | House | House sustained Governor's veto |
| 2024-04-08 | Governor: Vetoed by Governor | |
| 2024-03-27 | Governor: Governor's Action Deadline 11:59 p.m., April 8, 2024 | |
| 2024-03-27 | House | Enrolled Bill communicated to Governor on March 27, 2024 |
| 2024-03-26 | House | Signed by Speaker |
| 2024-03-25 | Senate | Signed by President |
| 2024-03-25 | House | Bill text as passed House and Senate (HB570ER) |
| 2024-03-25 | House | Enrolled |
| 2024-03-05 | Senate | Passed Senate (25-Y 15-N) |
| 2024-03-05 | Senate | Read third time |
| 2024-03-04 | Senate | Constitutional reading dispensed (40-Y 0-N) |
| 2024-02-29 | Senate | Reported from Finance and Appropriations (10-Y 4-N) |
| 2024-02-26 | Senate | Rereferred to Finance and Appropriations |
| 2024-02-26 | Senate | Reported from Commerce and Labor (10-Y 5-N) |
| 2024-02-22 | Senate | Rereferred to Commerce and Labor |
| 2024-02-22 | Senate | Rereferred from Education and Health (12-Y 0-N) |
| 2024-02-14 | Senate | Referred to Committee on Education and Health |
| 2024-02-14 | Senate | Constitutional reading dispensed |
| 2024-02-13 | House | VOTE: Passage (52-Y 46-N) |
| 2024-02-13 | House | Read third time and passed House (52-Y 46-N) |
| 2024-02-12 | House | Engrossed by House - committee substitute HB570H1 |
| 2024-02-12 | House | Committee substitute agreed to 24106760D-H1 |
| 2024-02-12 | House | Read second time |
| 2024-02-11 | House | Read first time |
| 2024-02-09 | House | Reported from Appropriations (11-Y 9-N) |
| 2024-02-07 | House | Subcommittee recommends reporting (5-Y 2-N) |
| 2024-02-01 | House | Assigned App. sub: Health & Human Resources |
| 2024-02-01 | House | Referred to Committee on Appropriations |
| 2024-02-01 | House | Committee substitute printed 24106760D-H1 |
| 2024-02-01 | House | Reported from Labor and Commerce with substitute (12-Y 10-N) |
| 2024-01-30 | House | Assigned L & C sub: Subcommittee #1 |
| 2024-01-25 | House | Referred to Committee on Labor and Commerce |
| 2024-01-25 | House | Referred from Health and Human Services by voice vote |
| 2024-01-09 | House | Referred to Committee on Health and Human Services |
| 2024-01-09 | House | Prefiled and ordered printed; offered 01/10/24 24100122D |
Same As/Similar To
SB274 (Similar To) 2024-04-17 - Senate sustained Governor's veto
Subjects
Commissions Boards and Institutions Generally
Health
Prescription Medicines
Professions and Occupations
Study Commissions Committees and Reports
Health
Prescription Medicines
Professions and Occupations
Study Commissions Committees and Reports
Code Citations
| Chapter | Article | Section | Citation Type | Statute Text |
|---|---|---|---|---|
| 32 | 1 | 276.12 | (n/a) | See Bill Text |
| 32 | 1 | 276.19 | (n/a) | See Bill Text |
| 54 | 1 | 3442.02 | (n/a) | See Bill Text |
